MétaCan
Menu
Back to cohort
Record W2949376168 · doi:10.1002/hon.131_2631

PRIMARY PANCREATIC LYMPHOMA: CLINICAL PRESENTATION, DIAGNOSIS, TREATMENT AND OUTCOME IN A MULTICENTRIC ITALIAN EXPERIENCE

2019· article· en· W2949376168 on OpenAlexaff
Davide Facchinelli, Enrico Boninsegna, Sokol Sina, Alex Borin, Maria Chiara Tisi, Francesco Piazza, Greta Scapinello, Elena Maiolo, M. Merli, Piero Maria Stefani, Marco Basso, Attilio Parisi, Erminia Manfrin, Mauro Krampera, Carlo Visco, Cristina Tecchio

Bibliographic record

VenueHematological Oncology · 2019
Typearticle
Languageen
FieldMedicine
TopicLymphoma Diagnosis and Treatment
Canadian institutionsPancreas Centre (Canada)
Fundersnot available
KeywordsMedicineInternal medicineChemotherapyHematologyLymphomaMedical recordInternational Prognostic IndexGastroenterologyRadiation therapyOncologyDiffuse large B-cell lymphoma

Abstract

fetched live from OpenAlex

Introduction: Primary Pancreatic Lymphoma (PPL) is a very rare disease, representing only 0.1% of lymphomas and 0.2% of pancreatic tumors. PPL presentation is variable and may overlap the onset of other neoplastic or inflammatory pancreatic diseases, often resulting in diagnostic difficulties. Due to the limited number of PPL study series, standardized diagnostic and therapeutic protocols are currently lacking. Methods: Diagnostic criteria for PPL were established according to the “Fourth WHO Classification of digestive tumors”. Clinical and treatment data of patients diagnosed with PPL between 2005 and 2018 were retrieved from medical record databases of 7 Italian Hematology Units. Overall survival (OS) and progression free survival (PFS) were calculated according the Kaplan Meier test and compared by the log-rank test. Results: Overall 37 patients were affected by PPL. Clinical manifestations at diagnosis are summarized in the table. Most patients (83%) had a high grade B cell histotype. Fifty nine % of patients were first line treated with chemotherapy, 21% with chemo + radiotherapy, 10% with surgery + chemotherapy, 3% with surgery and 7% did not received any treatment. With a median follow up of 37.5 months the 2 year OS is 59% while the 2 year PFS is 45%. Provided the relatively low number of cases, patients with low grade lymphomas and a good risk Revised International Prognostic Index (R-IPI) had better median OS (not reached vs 26 months and not reached vs 8 months, p=0.31 and 0.001) and PFS (not reached vs 108 months and 108 vs 8 months, p=0.095 and 0.01) as compared to the others. There were no differences in OS and PFS beetween chemotherapy or chemo-radiotherapy treatments (p=0.8 and 0.33) while patients who underwent debulking surgery (alone or + chemotherapy) had a significant worse OS as compared to those treated with chemotherapy alone (median not reached vs 6 months, p=0.033). Importantly 3/28 (10.7%) patients with high grade PPL experienced a central nervous system (CNS) relapse of disease. Conclusions: PPL represents a rare and difficult-to-recognize disease with symptoms and pancreatic gland localization superimposable to those of pancreatic ductal adenocarcinoma. Most PPL are high grade non Hodgkin lymphoma. According to our study biopsy should be the preferred diagnostic method since debulking surgery was associated with a worse OS. The high CNS relapse rate suggests that patients with high grade PPL should receive CNS directed prophylaxis. Keywords: extranodal lymphomas.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.021
Threshold uncertainty score0.647

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.069
GPT teacher head0.404
Teacher spread0.335 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueHematological OncologySame topicLymphoma Diagnosis and TreatmentFrench-language works237,207